Stopping blood pressure medication safely: a UK guide

The underrecognised problem: blood pressure medication that is no longer needed

Blood pressure medication is typically started when a reading threshold is crossed. It is rarely stopped when that threshold is no longer relevant — after meaningful weight loss, increased physical activity, reduced alcohol intake, or dietary change. The result is a significant population of patients who are on antihypertensives that are now causing their blood pressure to run too low.

A 2021 Cochrane review found that deprescribing antihypertensives in older adults and patients who had achieved significant lifestyle improvements was feasible in a substantial proportion, without significant cardiovascular risk when done under supervision. [1] This is not a fringe view — it is an evidence-based clinical position that is simply not widely actioned.

Which patients are most likely to no longer need their antihypertensives

The clearest candidates are those for whom the hypertension was not truly "essential" — where a modifiable driver was present and has since been addressed. The four most common scenarios in clinical practice: significant weight loss (approximately 1 mmHg systolic reduction per kilogram lost [2]); increased aerobic exercise (5–8 mmHg systolic reduction with sustained exercise [3]); substantial alcohol reduction (alcohol is a major reversible driver of hypertension that almost never features in the initial prescribing conversation); and dietary sodium reduction.

The 90–95% of hypertension labelled "essential" does not mean untreatable without medication — it means no secondary cause was identified. Many of these patients had modifiable drivers that were never formally addressed. The label is about aetiology, not treatability.

What NICE says about stopping antihypertensives

NICE NG136 (hypertension, 2023) does not provide a specific deprescribing pathway but does recommend that antihypertensive treatment be reviewed if patients achieve significant lifestyle improvements, and that monitoring continues after any medication change. [4] It supports a trial of stopping in patients who have sustained low blood pressure readings after lifestyle modification, under clinical supervision.

NHS England's structured medication review (SMR) framework explicitly includes antihypertensives as a drug class to review for ongoing appropriateness in patients who have experienced significant clinical change. [5]

Which antihypertensives require tapering and which do not

Beta-blockers (atenolol, bisoprolol, metoprolol): never stop abruptly. Rebound hypertension and, in patients with ischaemic heart disease, rebound angina or cardiac events are well-recognised risks of abrupt beta-blocker withdrawal. Taper over two to four weeks minimum. [4]

ACE inhibitors and ARBs (ramipril, lisinopril, amlodipine, losartan): no pharmacological withdrawal syndrome but blood pressure should be monitored closely after stopping. Can be reduced by one step before stopping completely.

Calcium channel blockers (amlodipine, felodipine): generally safe to stop without tapering but blood pressure monitoring in the first two weeks is important.

Thiazide diuretics (indapamide, bendroflumethiazide): no significant withdrawal effect but stopping requires blood pressure monitoring.

How to monitor after stopping

Home blood pressure monitoring is the essential tool. Check blood pressure twice daily for the first two weeks after stopping or reducing antihypertensives — morning and evening, sitting, after five minutes of rest. Record the readings. A sustained rise above 140/90 in patients under 80, or 150/90 in patients over 80, warrants GP review of whether medication needs restarting. [4]

Orthostatic hypotension — dizziness on standing — is more likely during dose reduction than after stopping, as the relative excess of antihypertensive effect is greatest during transition. Check blood pressure sitting and standing during any transition.

The weight loss connection

Patients who have lost significant weight on GLP-1 medication frequently find themselves over-treated with antihypertensives. The blood pressure reduction from weight loss compounds GLP-1's modest direct antihypertensive effect, and the total reduction can be substantial — easily 15–20 mmHg systolic in a patient who has lost 15–20 kg. This is the most common clinical scenario in which antihypertensive deprescribing becomes immediately relevant. Read more in blood pressure after weight loss.